R R

What Is Nourianz?

Nourianz is a prescription medication containing istradefylline, an adenosine receptor antagonist used in adults with Parkinson's disease. It is approved as an additional treatment alongside levodopa and carbidopa for patients experiencing OFF episodes. These episodes occur when Parkinson's symptoms return or worsen as the effects of medication diminish. Nourianz is taken as an oral tablet once daily. It helps reduce OFF time but does not cure Parkinson's disease or replace the patient's existing levodopa and carbidopa treatment.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Nourianz?

Nourianz is a prescription medication containing istradefylline, an adenosine receptor antagonist used in adults with Parkinson's disease. It is approved as an additional treatment alongside levodopa and carbidopa for patients experiencing OFF episodes. These episodes occur when Parkinson's symptoms return or worsen as the effects of medication diminish. Nourianz is taken as an oral tablet once daily. It helps reduce OFF time but does not cure Parkinson's disease or replace the patient's existing levodopa and carbidopa treatment.

read more about nourianz ...

Copy this HTML:

Copy HTML Copied!

How Does Nourianz Work?

Nourianz selectively blocks adenosine A2A receptors in the brain, particularly in areas involved in movement regulation. Adenosine signaling interacts with pathways that influence motor activity in Parkinson's disease. By blocking these receptors, istradefylline can help reduce the duration of OFF episodes experienced by patients taking levodopa and carbidopa. Its exact therapeutic mechanism in Parkinson's disease is not completely understood. Unlike levodopa, Nourianz does not directly replace dopamine in the brain.

Who Can Benefit From Nourianz Treatment?

Nourianz is approved for adults with Parkinson's disease who experience OFF episodes despite treatment with levodopa and carbidopa. These episodes can involve the return of stiffness, slowed movements, tremor, or other motor symptoms before the next medication dose takes effect. Nourianz is an adjunctive treatment and is not approved as a replacement for levodopa and carbidopa. A neurological specialist evaluates OFF time, existing medications, liver function, smoking history, and potential treatment risks before prescribing it.

How Should Nourianz Be Taken?

The recommended starting dose of Nourianz is 20 mg orally once daily, with or without food. The dose can be increased to a maximum of 40 mg daily according to response and tolerability. Patients taking strong CYP3A4 inhibitors or those with moderate liver impairment should not exceed 20 mg daily. People who smoke at least 20 cigarettes daily or an equivalent amount of tobacco have a recommended dose of 40 mg daily. Patients should follow their prescribed schedule and report changes in smoking habits.

What Are the Side Effects and Warnings of Nourianz?

Common side effects include involuntary movements, dizziness, constipation, nausea, hallucinations, and difficulty sleeping. Nourianz can cause or worsen dyskinesia in patients taking levodopa. Some patients experience hallucinations, psychotic behavior, or unusual compulsive urges such as excessive gambling or shopping. Drug interactions can alter istradefylline exposure, and patients with significant liver impairment require special precautions. Nourianz can harm an unborn baby, so pregnancy considerations should be discussed before treatment.

Common Questions About Nourianz

What is Nourianz used for?

Nourianz is prescribed alongside levodopa and carbidopa to reduce OFF episodes in adults with Parkinson's disease. It is not intended to replace their existing treatment.

Is Nourianz a dopamine agonist?

No. Nourianz is an adenosine A2A receptor antagonist. It works differently from dopamine agonists and levodopa.

How often is Nourianz taken?

Nourianz is taken once daily, usually starting at 20 mg. The prescribed dose can vary according to response, medication interactions, liver function, and tobacco use.

Can Nourianz cause involuntary movements?

Yes. Nourianz can cause or worsen dyskinesia, particularly in patients already taking levodopa. New or troublesome involuntary movements should be reported to the treating clinician.

References

DailyMed - NOURIANZ (istradefylline) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7d008cb-b273-4049-a5d2-9c6902910d58. Date Accessed October 19, 2026.

Istradefylline. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK575292/. Date Accessed October 19, 2026.

Istradefylline. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619053.html. Date Accessed October 19, 2026.

Istradefylline. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Istradefylline. Date Accessed October 19, 2026.

NOURIANZ (istradefylline) Full Prescribing Information. Kyowa Kirin. https://www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf. Date Accessed October 19, 2026.